Alphavirus immunotherapy of NPM/ALK+ anaplastic large cell lymphoma in a mouse model

2574 Background: \batchmode \documentclass[fleqn,10pt,legalpaper]{article} \usepackage{amssymb} \usepackage{amsfonts} \usepackage{amsmath} \pagestyle{empty} \begin{document} \(\underline{\mathrm{A}}\) \end{document}naplastic \batchmode \documentclass[fleqn,10pt,legalpaper]{article} \usepackage{amssymb} \usepackage{amsfonts} \usepackage{amsmath} \pagestyle{empty} \begin{document} \(\underline{\mathrm{L}}\) \end{document}arge \batchmode \documentclass[fleqn,10pt,legalpaper]{article} \usepackage{amssymb} \usepackage{amsfonts} \usepackage{amsmath} \pagestyle{empty} \begin{document} \(\underline{\mathrm{C}}\) \end{document}ell \batchmode \documentclass[fleqn,10pt,legalpaper]{article} \usepackage{amssymb} \usepackage{amsfonts} \usepackage{amsmath} \pagestyle{empty} \begin{document} \(\underline{\mathrm{L}}\) \end{document}ymphoma (ALCL) is a non-Hodgkin's lymphoma. 2/3 of Kit+ (CD30) ALCL cases are associated with the expression of the fusion oncogene, NPM/ALK. Due to the effective immunogenicity of Venezuelan ...